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Localizing the cellular prion protein (PrP C) in the brain is necessary for understanding the pathogenesis of prion diseases. However, the
precise ultrastructural localization of PrP C still remains enigmatic. We performed the first quantitative study of the ultrastructural
localization of PrP C in the mouse hippocampus using high-resolution cryoimmunogold electron microscopy. PrP C follows the standard
biosynthetic trafficking pathway with a preferential localization in late endosomal compartments and on the plasma membrane of
neurons and neuronal processes. PrP C is found with the same frequency within the synaptic specialization and perisynaptically, but is
almost completely excluded from synaptic vesicles. Unexpectedly, PrP is also found in the cytosol in subpopulations of neurons in the
hippocampus, neocortex, and thalamus but not the cerebellum. Cytosolic PrP may have altered susceptibility to aggregation, suggesting
that these neurons might play a significant role in the pathogenesis of prion diseases, in particular those mammals harboring mutant PrP
genes.
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Introduction
The cellular prion protein (PrP C) is a cell-surface glycoprotein
anchored by a glycosylphosphatidylinositol (GPI) moiety (Stahl
et al., 1987). PrP C is expressed throughout the brain, particularly
in neurons (Kretzschmar et al., 1986; Moser et al., 1995) and to a
lesser extent in extraneural tissues (Bendheim et al., 1992; Ford et
al., 2002). In prion diseases, PrP C is converted to an abnormal,
conformationally altered isoform (PrP Sc), which subsequently
accumulates in the brain and results in extensive neurodegenera-
tion with an inevitably fatal outcome (Prusiner, 1996). Therefore,
localizing PrP C in the brain is an important step in understanding
the biology of the normal protein and mapping changes in mod-
els of experimental prion diseases.
The precise localization of PrP C remains enigmatic because of
conflicting data obtained using different techniques. Immuno-
histochemical studies described a somatic expression of PrP C in
neurons with no signal or only a minor signal in the neuropil
(DeArmond et al., 1987; Piccardo et al., 1990; Safar et al., 1990;
Bendheim et al., 1992; Verghese-Nikolakaki et al., 1999; Ford et
al., 2002). However, it was not determined whether PrP C was
luminal [for example, in the endoplasmic reticulum (ER) or
Golgi] or cytosolic. Data obtained using free-floating section im-
munohistochemistry (Sales et al., 1998; Haeberle et al., 2000;
Moya et al., 2000) and immunoelectron microscopy (Fournier et
al., 1995, 2000) indicated PrP C localization in the neuropil with a
synaptic membrane prevalence. However, data obtained from
synaptosomal preparations (Herms et al., 1999) and a recent ul-
trastructural study on the distribution of PrP C in the cerebellum
(Laine et al., 2001) have favored a predominantly plasma mem-
brane location of PrP C with no expression on synaptic vesicles or
in the cytoplasm. These contradictory findings probably reflect
the peculiarities inherently associated with pre-embedding tech-
niques. Many immunoelectron microscopic procedures may re-
sult in a destruction of cellular membranes, possibly leading to an
artificial redistribution of GPI-anchored proteins within the
membrane (Griffiths, 1993).
Two recently published studies on the effects of proteosome
inhibitors on PrP C degradation and expression of cytosolic PrP
suggested that cytosolic localization of PrP is sufficient to induce
neurodegeneration (Ma and Lindquist, 2002; Ma et al., 2002). It
is notable that under the experimental conditions of these stud-
ies, PrP becomes insoluble and acquires partial protease
resistance.
These uncertainties regarding the precise subcellular localiza-
tion of PrP C therefore encouraged us to perform the first quan-
titative study of ultrastructural PrP C localization in the mouse
brain. We used a sensitive, high-resolution detection method
combining immunofluoresence and immunogold labeling of 500
and 60 nm cryosections at light and electron microscopy levels,
respectively. The method uses glutaraldehyde for both optimal
fixation and preventing migration of GPI-anchored proteins and
circumvents the need for alcohol dehydration. Because of its po-
tentially important role in the pathogenesis of prion diseases
(DeArmond et al., 1987; Taraboulos et al., 1992a), we focused on
the localization of PrP C in the hippocampus and show for the
first time quantitative data of PrP C distribution at the ultrastruc-
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tural level throughout the CA1 and dentate gyrus areas. We lo-
calized PrP C on all biosynthetic and endocytic transport mem-
branous structures of hippocampal neurons, but almost no PrP C
was found in synaptic vesicles. In addition, we discovered a subset
of neurons in which PrP is located predominantly in the cytosol.
These cells did not show any obvious signs of neurodegeneration
but may have important implications in the pathogenesis of
prion diseases.
Materials and Methods
Animals and preparation of tissue. Brain tissue was obtained from 22 mice
at12 weeks of age from four different mouse lines with the FVB back-
ground: (1) wild-type (wt) mice, (2) PrP-ablated (Prnp 0/0) mice (Bu¨eler
et al., 1993), (3) transgenic 4053 mice overexpressing mouse PrP C (Tell-
ing et al., 1996), and (4) transgenic 3045 mice overexpressing hamster
PrP C (Telling et al., 1996). According to PHS–NIH Guide for the Care and
Use of Laboratory Animals, the mice were deeply anesthetized with Nem-
butal and perfused transcardially, first with PBS plus heparin (1 l/ml)
for 90 sec, then with PBS for 1 min, and finally with one of the following
fixatives for 5 min: 2% paraformaldehyde (PFA) in PIPES-HEPES-
EGTA-magnesium (PHEM) buffer (25 mM HEPES, 10 mM EGTA, 60 mM
PIPES, 2 mM MgCl2, pH 7.2) (four B4053 mice); 2% PFA–0.2% glutaral-
dehyde (GA) in PHEM buffer, pH 7.2 (four B4053 mice, four wt mice, two
A3045 mice, two Prnp0/0 mice); periodate-lysine-paraformaldehyde (PLP)
fixative (McLean and Nakane, 1974) with a final concentration of 2% PFA
(four B4053 mice); and 2% PFA–0.2% GA in PHEM buffer, pH 7.2 (two
B4053 mice). After perfusion, the brains were collected, postfixed in the same
fixative for 1 hr at 4°C, washed in PHEM four times, and stored at 4°C in
0.5% PFA in PHEM buffer, pH 7.2.
Reagents and antibodies. PrP-specific recombinant antibody fragments
(Fabs) D13, D18, R1, R2, E123, and E149 were derived from phage librar-
ies and have been characterized thoroughly (Peretz et al., 1997; William-
son et al., 1998; Leclerc et al., 2001; Peretz et al., 2001). SAF32 and 8H4
monoclonal antibodies were gifts from Dr. H. Axelrad (Faculty of Med-
icine, Pitié-Salpeˆtrière, Paris, France). An aliquot of Fab D18 was conju-
gated to UltraSmall gold particles (0.8 nm; Aurion, Wageningen, The
Netherlands) to allow increased penetration into the cryosections and
circumvent labeling artifacts caused by a cross-reaction with immuno-
globulins in the tissue. R-GENT SE-EM and R-GENT SE-LM silver en-
hancement kits were purchased from Aurion. The in situ cell death de-
tection kit [terminal deoxynucleotidyl transferase-mediated biotinylated
UTP nick end labeling (TUNEL)] was purchased from Roche Products
(Mannheim, Germany).
Polyclonal and monoclonal antibodies against GABA, monoclonal an-
tibodies against parvalbumin, and monoclonal 2,3-cyclic nucleotide
3-phosphodiesterase (CNPase) antibodies were obtained from Sigma
(St. Louis, MO). Polyclonal antibodies against parvalbumin, calretinin,
and calbindin D28K were obtained from Swant (Bellinzona, Switzer-
land). Polyclonal antibodies against somatostatin and b-NOS were pur-
chased from Chemicon (Temecula, CA), and monoclonal antibodies
against synaptobrevin/vesicle-associated membrane protein-2 (Vamp2)
were purchased from Synaptic Systems (Go¨ttingen, Germany). Poly-
clonal GFAP and S100 antibodies were purchased from Dako (Glostrup,
Denmark), goat polyclonal Thy-1 (GPI-anchored protein) antibodies
and rabbit polyclonal antibodies against neuropeptide Y were obtained
from Research Diagnostics (Flanders, NJ), and polyclonal antibodies
against vasointestinal peptide were purchased from DiaSorin (Antony,
France). Rabbit anti-mouse Fab and rabbit anti-mouse IgG antibodies
were obtained from Pierce (Rockford, IL). Secondary anti-mouse, anti-
rabbit antibodies conjugated with Alexa Fluor 488 or Texas Red were
purchased from Molecular Probes (Eugene, OR). Protein-A– gold con-
jugates were obtained from Utrecht Medical School (The Netherlands).
Cryosectioning and immunolabeling. Cryosections were prepared as
described previously (Peters, 2001). Briefly, the fixed specimens were
infused with 2.3 M sucrose overnight and then frozen in liquid nitrogen.
Both semithin (0.5m) and ultrathin sections (60 nm) were cut at100
or120°C with a diamond knife on a Leica (Vienna, Austria) Ultracut T
equipped with a cryoattachment. Semithin sections were picked up from
the diamond knife using 2.3 M sucrose and transferred to a glass slide for
subsequent immunohistochemical labeling. For light microscopy, pri-
mary antibodies were detected using either secondary antibodies conju-
gated with Alexa Fluor 488 or Texas Red or secondary rabbit “bridging”
antibodies with protein A-gold (5 nm), which was silver-enhanced with
Aurion R-GENT SE–LM kit for 15 min. Ultrathin sections were picked
up from the diamond knife with a 1% methyl cellulose 25CP–1.15 M
sucrose solution and transferred to formvar/carbon-coated copper grids.
The immunolabeling of sections was done as described previously
(Raposo et al., 1997). In brief, after blocking with 1% cold fish gelatin and
1% bovine serum albumin for 15 min, sections were incubated with
primary antibody for 60 min, washed, and bridging rabbit antibodies
were applied for 30 min when necessary. Sections were then incubated
with protein A-gold (10 nm) for 20 min. For the double-labeling exper-
iments, a second primary antibody followed by protein A-gold was ap-
plied consecutively after labeling with the first antibody. To rule out the
possibility that noncolocalization could be attributable to interference by
the primary antibody, we compared the density of immunogold labeling
of each antibody in single-immunolabeling procedures or omitted one of
the primary antibodies in double-labeling experiments. No significant
interference was observed. Fab D18 against PrP C covalently conjugated
with 0.8 nm UltraSmall gold particles was also used to label PrP. Ultra-
Small gold particles were visualized using the R-GENT SE–EM silver
enhancement kit, following the instructions of the manufacturer. La-
beled sections were viewed with a Philips CM10 electron microscope
(FEI Company, Eindhoven, The Netherlands) at 80 kV and a standard
15,000magnification.
Although cryoultramicrotomy uses a different contrast-staining
method from routine epon ultramicrotomy, cellular and subcellular pro-
files of cells appear similar under the electron microscope (Maunsbach
and Afzelius, 1999). The only differences are the reverse contrast of mem-
branes, which appear white, and the cytoplasm, which becomes electron
dense. Cellular and subcellular profiles were thus identified and defined
according to the criteria of Peters et al. (1991).
Quantification of immunogold labeling. Quantitative evaluation of hip-
pocampal labeling was performed only on ultrathin cryosections of wt
FVB mice that were fixed with 2% PFA– 0.2% GA to avoid overexpres-
sion artifacts of the transgenes. The relative distributions of labeled PrP C
were determined by counting gold particles over plasma and intracellular
membranes of selected hippocampal cells. We estimated the membrane
(gold per micrometer) and area (gold per square micrometer) labeling
density on micrographs with a final 32,000 magnification by using
point and intersection counting with a line and point lattice (10 mm
distance) overlay as described by Weibel (1979) and Griffiths (1993).
Gold particles located 20 nm from a visible membrane structure were
assigned to that structure. The distance of 20 nm was chosen on the basis
of the distance constraints of immunolabeling described below.
We used two labeling protocols on ultrathin cryosections. The first
included the application of a murine Fab fragment, followed by a rabbit
anti-mouse anti-Fab IgG and protein A coupled to a 10 nm gold particle.
According to Griffiths (1993) and Amit et al. (1986), the length of an IgG
molecule in projection is8 –10 nm, and a Fab fragment is5 nm. The
diameter of the protein A-gold (10 nm) complex is 12–13 nm, but
because we measure the distance to the center of the gold particle, we
should consider only its radius (6 –7 nm). In summary, the complex
consisting of a Fab, IgG, and protein A-gold has a projection of 19 –22
nm. Therefore, we used a 20 nm radius to assign gold particles to a
specific structure on the sections.
The second labeling protocol involves the application of recombinant
Fab fragments directly conjugated with UltraSmall gold particles (0.8
nm) and the subsequent silver enhancement for better visualization. In
this case, the distance between the antigen and the center of the gold
particle is 6 nm. The silver enhancement procedure deposits silver
around the gold particle without preferential orientation, practically iso-
tropic. Therefore, the position of the enhanced gold particle (10 –15 nm
in diameter) will precisely indicate the localization of the antigen of
interest.
We analyzed cells taken from a vertical strip running through CA1
from the stratum oriens to the hilus of the dentate gyrus. This included
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cells from the pyramidal cell layer and hilus, as well as dentate granule
cells. Ten random pictures with good ultrastructural preservation were
taken from each area on sections from 18 grids made from three animal
samples (six grids for each sample). The gold particles were counted in
the following subcellular structures: endoplasmic reticulum (including
the nuclear envelope), Golgi complex, endosomes and lysosomes, tu-
bules and vesicles without definite coat, clathrin-coated vesicles and pits,
plasma membrane, mitochondria, and nucleus. Immunogold labeling
on mitochondria was treated as background labeling, because PrP C has
never been observed on these organelles by either biochemical or mor-
phological methods by us or by others.
In addition, we analyzed the distribution of gold particles in the neu-
ropil of the strata radiatum, oriens, and moleculare of the dentate gyrus,
on membrane profiles in dendrites and axons, and on membranes of
synaptic and perisynaptic profiles. Each class was further subdivided into
the plasma membrane, internal transport vesicles, spines and endosomes
(only for dendrites), mitochondria, and myelin sheaths (only for axons).
Membranes of synaptic complexes were classified into synaptic vesicles,
synaptic specialization (which included the two closely opposed mem-
branes in the synapse), and the presynaptic and postsynaptic membrane
(which include the membranes outside the synaptic specialization re-
gion). For our cryosections, we used the same standard criteria for sub-
cellular structures in brain cells as those used in epon sections (Peters et
al., 1991). Unidentified membrane compartments were not taken into
account, because they did not show substantial labeling and represented
only5% of all cellular membranes.
To test that the labeling for PrP was not random, we calculated the
relative labeling index (RLI) according to Mayhew et al. (2002). By su-
perimposing a test-point lattice on the electron micrographs, we gener-
ated random points ( P) on cellular compartments with the point density
determined by the relative size of each compartment. The number of
points was normalized to the number of observed gold particles (no),
giving a value for the expected distribution of labels (ne). The RLI is
calculated by dividing no by ne. Particle distributions were compared with
a 2 analysis to test whether the observed distributions differ significantly
from random distributions. The partial  2 value in each row in Table 4
was obtained using the following formula: (no  ne)
2/ne. The total 
2
value was obtained by taking the sum of the partial values. If a compart-
ment is randomly labeled, its RLI 1 and partial  2  0. If a compart-
ment is preferentially labeled, the RLI value will be1, and its partial  2
value will contribute a significant portion to the total  2 value.
Results
Assessment of methodology and antibodies
Four different fixatives were examined to find the optimal con-
ditions for both ultrastructural integrity and preservation of an-
tigenicity. We found that both PLP and 2% PFA fixatives resulted
in suboptimal ultrastructure preservation for ultrathin cryosec-
tions (our unpublished data). A fixative composed of both PFA
and GA gave the best results for ultrastructural integrity and an-
tigen preservation. However, the distribution of immunolabeling
was the same with all fixatives used (data not shown). Thus, we
used the fixative containing 2% PFA and 0.2% GA for the immu-
nolabeling experiments.
Raising antibodies against PrP has been difficult because of
the high degree of conservation of PrP sequences between species
and the inhibitory activity of anti-PrP antibodies toward lym-
phocytes. To circumvent this problem, we used well character-
ized recombinant Fabs that recognize different parts of the PrP C
molecule (Peretz et al., 1997; Leclerc et al., 2001): E123 (residues
23–37), E149 (residues 72– 86), D13 (residues 96 –104), D18 (res-
idues 133–157), and R1 and R2 (residues 225–231). These Fabs
were obtained from immunized Prnp 0/0 mice and retrieved
through phage display libraries and have been shown as reliable
immunoreagents that recognize PrP C in different experimental
procedures (Williamson et al., 1996, 1998; Leclerc et al., 2001;
Peretz et al., 2001). Monoclonal antibodies 8H4 (which recog-
nizes residues 158 –174) and SAF32 (which recognizes residues
52–92) were used as additional positive controls. We found no
differences in labeling patterns in the murine hippocampus be-
tween these different antibodies (data not shown).
Distribution of PrP C observed by light microscopy
To determine the precise localization of PrP C, we used cryopro-
tected aldehyde-fixed tissue samples, which allowed us to make
both semithin (0.5 m) and ultrathin (60 nm) sections from the
very same block in a serial manner. Thus, we had the ability to
easily correlate immunolabeling at cellular and subcellular levels.
We used two markers for semithin cryosections: (1) gold particles
that were silver enhanced (Fig. 1A) and (2) a fluorescent dye
marker (Fig. 1C). Both methods clearly showed that PrP C was
found predominantly in the neuropil in all hippocampal layers,
with a higher density in the strata oriens and radiatum, moderate
immunoreactivity in the stratum lacunosum-moleculare, and
weak labeling in the stratum moleculare and hilus (Fig. 1A,C).
No significant differences in labeling intensity were observed
among the CA1, CA2, and CA3 areas of the hippocampus (data
not shown). Dendrites of pyramidal cells were mostly immuno-
Figure 1. Hippocampal (CA1 and dentate gyrus) semithin cryosections labeled for PrP C with Fab
D18. Labeling is concentrated in the stratum oriens (o), stratum radiatum (r), and lacunosum-
moleculare (lm); less labeling is seen in the stratum moleculare (m) and hilus (h) of the dentate gyrus.
Cell bodies in pyramidal (p) and granule (g) layers are free of labeling, with the exception of rare cells
( D). A, Hippocampus of a wt FVB mouse. Fab D18 was used with a secondary polyclonal antibody and
protein A-gold (5 nm) that was subsequently visualized by silver enhancement (Aurion). B, Hip-
pocampus of a Prnp 0/0 mouse. Labeling is the same as in A. No positive signal is visible. Sections are
counterstained with Giemsa. C, Hippocampus of a wt FVB mouse. Fluorescent labeling shows a label-
ing pattern similar to A. The arrow points to a cell with intense PrP C labeling. The box shows the cell
enlarged in D. D, A magnified view of a cell with high PrP C content. E, Hippocampus (CA1 area) of a
4053mousethatoverexpressesPrP,showingapatternofPrP ClabelingsimilartoAandC.Arrowspointtothe
cellswithanabundanceofPrPinthecytoplasm.F,CerebellumofawtFVBmouse.Nocellslabelingpositively
forPrP C inthecytoplasmwerefoundinthecerebellum.Purkinjecells(p)arefreeofintensivecytosolic label-
ing.Onlyfaintpunctatelabelingisvisible.Scalebars,100m.
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negative inside the profile and seen as
empty profiles embedded in positive sur-
roundings (Fig. 1A,C,D). This apparently
reflected the membranous localization of
PrP C [see electron microscopy (EM) study
below]. Specificity of the PrP C antibodies
was confirmed by the absence of staining
in the hippocampus with the omission of
primary antibody and tissue from a
Prnp 0/0 mouse (Fig. 1B).
We consistently saw a small population
of cell bodies that were intensely labeled by
both the immunogold and immunofluo-
rescence procedures (Fig. 1C–E). These
cells with high PrP C content in cell bodies
were found with similar frequency in three
of the mouse lines (wt FVB, 4053, 3405)
and were absent in Prnp 0/0 mice. These
cells were concentrated predominantly in
the CA1 area in the strata pyramidale and
oriens with a frequency of 1–2% of all cells.
Furthermore, they were practically absent
from the CA3 area and occasionally seen as
small groups in the dentate gyrus. In addi-
tion, a small number of cells with high
PrP C labeling in cell bodies was seen in the
somatosensory neocortex (layers V and
VI) and ventral lateral geniculate nucleus
of the thalamus (data not shown). We re-
fer to these cells as cytosolic PrP (CPrP)
cells.
We did not observe any CPrP cells in
the cerebellum of any of the murine lines
that we analyzed. The immunofluorescent
labeling of cerebellar PrP C was concen-
trated in the neuropil areas of the molecu-
lar layer and not in the cell bodies (Fig.
1F). In the neocortex and hippocampus,
very weak punctate labeling in the cyto-
plasm of cerebellar neurons reflected PrP C
localization in intracellular organelles,
which was confirmed by subsequent EM
analysis (data not shown).
Ultrastructural distribution of PrP C in
the hippocampus
To gain insight into the precise localiza-
tion of PrP C at the ultrastructural level, we
used the very same blocks to produce ul-
trathin sections immediately after cutting
semithin sections from the areas of interest. Thereby we could
assess identical structures at both light and electron microscopic
levels. By EM, PrP C labeling in the neuropil was predominantly
found on the plasma membrane of dendrites, including spines, as
well as dendritic transport vesicles, endosomes, axolemma, ax-
onal transport vesicles, and myelin sheaths. In addition, the
membranes of synaptic specializations, including presynaptic
and postsynaptic membranes, and of synaptic vesicles (Figs.
2B–E, 3A) labeled positively for PrP C. However, quantitative
analysis showed marked reduction of labeling on the synaptic
vesicle membrane (Table 1). Prnp 0/0 mice displayed no immu-
nopositive profiles for PrP C (Fig. 2A).
Light microscopy of immunolabeled sections suggested no
preferential accumulation of PrP C in the profiles of the neuropil.
Being aware that PrP C has been described previously as being
enriched in synapses (Sales et al., 1998; Fournier et al., 2000;
Haeberle et al., 2000; Moya et al., 2000), we checked the accessi-
bility of other synaptic proteins for immunolabeling on ultrathin
cryosections. In performing double-labeling experiments, we en-
countered the problem of false colocalization resulting from an
interaction between secondary antibodies and protein A-gold
(data not shown). We circumvented this artifact by using anti-
PrP C Fab fragments directly conjugated with UltraSmall Aurion
gold particles (0.8 nm) that were subsequently enlarged by silver
enhancement (Aurion). Despite a slight decrease in contrast and
section quality, this method excluded artifactual effects such as
Figure 2. Ultrastructural localization of PrP C in the neuropil in hippocampal CA1 area. Labeling was performed using Fab D18
and protein A-gold (10 nm). A, Absence of PrP C labeling in a Prnp 0/0 mouse. B, Stratum radiatum of a wt FVB mouse. Gold particles
are localized on the axolemma (white arrows), myelin sheaths (white arrowheads), putative axon terminal membranes (black
arrowheads), synaptic vesicles (black arrows), axonal transport vesicle (near asterisk), and synaptic specialization (double-headed arrow).
Gold particles without arrows belong to processes, which are difficult to identify as being either dendritic or axonal. C, Stratum radiatum
from a wt FVB mouse. As in B, gold particles can be found at the synaptic specialization (double-headed arrow) and on the membranes of
the postsynaptic profile (arrowhead). D, Stratum oriens of a wt FVB mouse. Gold particles are localized on the dendritic shaft (white
arrowheads), small processes (white arrows), and synaptic vesicles (black arrow). E, Stratum radiatum of a wt FVB mouse, longitudinal
section of a dendrite. Gold particles are localized on the dendritic shaft (white arrowheads), membrane of a spine (black arrowhead), and
small processes (white arrows). The particle inside the spine probably sits on the spinal apparatus, which is not clearly identifiable because
of the tangential orientation. Relative distribution of the immunogold labels is provided in Table 1; B and D do not reflect quantitative
information. ax, Myelinated axon; den, dendrite; m, mitochondria; sb, synaptic bouton; sp, spine. Scale bars, 200 nm.
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erroneous colocalization. Direct labeling with gold-conjugated
Fabs demonstrated a similar labeling pattern (Fig. 3A) to that
observed with indirect labeling using Fabs in combination with
secondary antibodies.
Sections were colabeled for the synaptic vesicle-specific pro-
tein synaptobrevin (VAMP2) and PrP C. As expected, VAMP2
was enriched in synaptic vesicles, whereas PrP C was primarily
seen on the plasma membrane (Fig. 3B). The levels of PrP C label-
ing in different layers of the hippocampus and in different pro-
files were assessed quantitatively, as described below.
In both neuronal and glial cells, PrP was detected on the ER,
Golgi complex, endosomes, uncoated transport vesicles, and
plasma membrane (Fig. 4A,B), which are important parts of the
biosynthetic and endocytic pathways. No labeling was detected in
the coated rims of Golgi cisternae (Fig. 4A), clathrin-coated pits
of the plasma membrane, or clathrin-coated vesicles (Fig. 4C).
Generally, immunolabeling was negligible or absent from mito-
chondrial and nuclear structures. Although the distribution of
PrP C in glial cells (confirmed by GFAP labeling) was not quanti-
fied, EM analysis suggests that they do not express PrP C at levels
comparable with neurons, because surrounding neuropil struc-
tures often had more gold particles than glial cells and their pro-
cesses (Fig. 5A,B, respectively). Electron micrographs from ul-
trathin sections, which were cut directly after semithin sections,
revealed the subcellular location of PrP in those neurons with cell
bodies that were immunopositive for PrP C (i.e., CPrP cells) by
light microscopy. Strikingly, the majority of the immunogold
particles was not associated with surrounding membranous
structures (Fig. 6A,D) but were located in the cytosol. Therefore,
we designate this form of PrP as “cytPrP.”
Morphologically, CPrP cells appear to have abundant dense
cytoplasms, long cisternae of the ER, well developed Golgi com-
plexes, endosomal and lysosomal structures, well structured mi-
tochondria, and often a nucleus with an irregular shape. The cells
show an irregular distribution of cytPrP, shifted to the periphery
of the cell and mostly excluded from the pericentrosomal region.
The cytosolic labeling can be classified as specific because it ex-
ceeded100 (see below) the background labeling in pyramidal
neurons, which were immunonegative by light microscopy. A
small number of gold particles was found in the lumen of biosyn-
thetic pathway organelles, such as the ER, Golgi complex, and
endosomes (Fig. 6A,B). From these data, we conclude that there
could be two isoforms of PrP C in these cells, one that is
membrane-bound and another that is cytosolic.
We detected cytPrP with Fabs recognizing the central region
(D18 and D13) (Fig. 6), N-terminal region (Est123 and Est149),
and C-terminal region (R1 and R2) of PrP C. Fab D18 conjugated
with UltraSmall gold gave the same pattern of labeling (Fig. 6D).
Furthermore, SAF32 and 8H4 monoclonal antibodies were
equally able to detect cytPrP (data not shown). This argues that
full-length PrP molecules that were present in the cytosol prob-
ably bound to some factor or aggregated into multimeric com-
plexes, which prevent diffusion into the nucleus. Theoretically, a
proteosome could cut PrP molecules into fragments, which are
recognizable by all applied antibodies. However, this scenario
seems much less likely, because either fragments of degraded pro-
teins are destroyed very quickly by various peptidases present in
the cytosol or the peptides should be detectable in the nucleus
where they are unavailable for degradation (Reits et al., 2003).
The soma and dendritic processes of cells with cytPrP receive
synaptic input from other neurons (Fig. 7A). Occasionally, ax-
onal terminals with unusually high labeling for PrP C were also
found in the neuropil (Fig. 7B). We assume that these axonal
terminals are derived from CPrP cells, but it remains to be proven
because of the low resolution of the immunogold method in
structures densely packed with membranes. Furthermore, CPrP
cells were negative for GFAP, CNPase, and S100 glial cells mark-
ers (data not shown), and their morphology was different to that
of glia but more closely resembled that of interneurons.
Figure 3. Ultrastructural localization of PrP C in the neuropil of the stratum radiatum in the
hippocampal CA1 area, using Fab D18 conjugated with UltraSmall gold and enhanced with a
silver enhancement kit. A, Membrane-bound localization of PrP C with dendritic cytosol free of
labeling. PrP C labeling was found on the dendritic shaft, axon terminal membrane, and profiles
of small processes. B, Double labeling for PrP C and VAMP2. Large particles (silver-enhanced
UltraSmall gold) (arrows) represent anti-PrP C labeling on the plasma membrane of the axon
terminal and dendrites; small (15 nm) gold particles indicate VAMP2 labeling of synaptic vesi-
cles. at, Axon terminal; den, dendrite; m, mitochondria; sb, synaptic bouton. Scale bars, 200 nm.
Table 1. Quantification of PrPC labeling density on the membranes of and within
dendritic, axonal, and synaptic profiles from the neuropil of the CA1 area and
dentate gyrusa
Membranous profiles
Neuropil area
Stratum oriens
(n 17)
Stratum radiatum
(n 20)
Stratum moleculare
(n 17)
Dendrites
Dendritic shaft 1.54 0.04 1.63 0.06 0.62 0.04
Spines 1.58 0.1 1.52 0.09 0.58 0.1
Transport vesicles/tubules 1.08 0.06 1.12 0.09 0.48 0.1
Endosomes/lysosomes 1.46 0.2 1.38 0.08 0.58 0.05
Axons
Axolemma 0.94 0.09 0.84 0.07 0.55 0.06
Transport vesicles/tubules 0.44 0.04 0.37 0.03 0.35 0.03
Myelin sheaths 0.38 0.05 0.35 0.03 0.36 0.04
Synaptic complexes
Presynaptic bouton 1.6 0.08 1.65 0.02 0.82 0.11
Synaptic specialization 1.51 0.15 1.48 0.2 0.79 0.12
Postsynaptic bouton 1.64 0.1 1.63 0.12 0.71 0.1
Synaptic vesicles 0.12 0.012 0.14 0.013 0.096 0.015
Mitochondria 0.056 0.014 0.073 0.016 0.04 0.008
aValues represent the number of gold particles per 1m of membrane (gold per micrometer). Mitochondria were
used to assess background labeling. Results are presented as mean SEM.
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Previous studies have shown that inhibitory interneurons may
play a prominent role in the pathogenesis of prion diseases (Be-
lichenko et al., 1999; Bouzamondo et al., 2000). Thus, we at-
tempted to determine whether these cells are indeed of the inter-
neuronal GABAergic type using several different markers for
particular cell populations. None of the CPrP cells were immu-
nopositive for calbindin, calreticulin, parvalbumin, vasointesti-
nal peptide, neuropeptide Y, somatostatin, and b-NOS (data not
shown). Therefore, the specific type of neurons to which CPrP
cells belong remains to be determined.
The cytosolic localization of PrP could reflect a particular state
of the neuron, which may cause or result from a dysfunction of
the machinery that generates GPI-anchored proteins. To check
for the latter possibility, we labeled these neurons for both PrP C
and another abundant GPI-anchored protein, Thy-1. In pyrami-
dal neurons as well as CPrP cells, the labeling against Thy-1 was
concentrated on late endosomes and the plasma membrane (Fig.
7C,D) without any indication of cytosolic distribution. This ar-
gues that the GPI-adding machinery functions normally in these
neurons, and another factor must account for the presence of
both cytosolic and membrane-bound PrP.
CPrP cells are neither necrotic nor apoptotic
Whether PrP accumulation in the cytosol reflects stress or
damage to the cells is unknown. However, morphological
examination of these neurons did not reveal organelle swelling
(mitochondria, ER, Golgi apparatus), disaggregation of polyri-
bosomes, or cell and nuclear membrane breaks that are clearly
indicative of neuronal necrosis. Furthermore, we did not observe
any apoptotic signs such as chromatin clumping, condensation of
cytoplasmic content, or accumulation of autophagic lysosomes.
Mitochondria displayed organized structure with well preserved
cristae, inner and outer membranes. Some of these neurons had a
denser cytosol than pyramidal neurons, but it was not a feature
distinguishing these neurons from others. We saw a number of
“dense cells” without signs of PrP accumulation in the cytosol
(Fig. 6C). Moreover, many neurons with cytPrP appeared to have
a normal cytosolic density, similar to other neurons. Although
morphological analysis remains the “gold standard” for assess-
ment and quantification of apoptosis (Hall, 1999), we neverthe-
less checked CPrP cells on semithin sections using an apoptosis
detection kit (on the basis of TUNEL methodology). None of the
CPrP cells appeared to be apoptotic (Fig. 8A–C).
Quantification of PrP C in the hippocampus
The use of gold particles and the good ultrastructural preserva-
tion produced by ultracryomicrotomy gave us the opportunity to
quantify the distribution of PrP C in the hippocampus. All seg-
ments of dendritic membranes (dendritic shaft, spines, transport
vesicles, and endocytic structures) showed approximately the
same density of gold particles per unit of membrane (Table 1).
The same structures in the molecular layer of the dentate gyrus
had less labeling than those in the strata oriens and radiatum,
matching precisely the labeling pattern observed by LM via im-
munofluorescence and silver enhancement. Axonal membranes
had a lower gold particle density than dendritic membranes. My-
elin sheaths were labeled with fewer gold particles per length of
Figure 4. PrP C labeling in neuronal cell bodies in the hippocampus of a wt FVB mouse. A,
Pyramidal neuron. Gold particles were found in the Golgi complex (arrowheads) and were
absent from coated rims (asterisks) of Golgi cisternae. B, Granule neuron from the dentate
gyrus. Gold particles are present in the nuclear envelope (arrow), which is a part of the ER, on
late endosomes–multivesicular bodies (mvb), and on the plasma membrane (arrowhead). C,
Pyramidal neuron. Gold particles are found on the plasma membrane (arrowheads) and early
endosomes (arrows) but not in clathrin-coated pits or clathrin-coated vesicles (asterisks). ee,
Early endosome; er, endoplasmic reticulum; G, Golgi complex; m, mitochondria; mvb, late en-
dosomal multivesicular body; n, nucleus; ne, nuclear envelope; pm, plasma membrane; aster-
isks, lumen of coated vesicles, pits, and rims. Scale bars, 200 nm.
Figure 5. PrP C is not enriched in astrocytes in the hippocampus. A, B, Astrocyte and astro-
cytic process. Double labeling for PrP C (small particles) and GFAP (large particles) is shown. Both
labels were enhanced with silver. PrP C is more concentrated on neuropil membranes (white
arrowheads) than on astrocytic membranes (black arrows). The dashed line in A delineates the
astrocytic plasma membrane. er, Endoplasmic reticulum; m, mitochondria; n, nucleus. Scale
bars, 200 nm.
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membrane than axolemma (Table 1). Interestingly, we found
similar PrP C concentrations on the membrane of presynaptic
and postsynaptic profiles and on those within the synapse. No
preferential labeling was observed within the synaptic specializa-
tion. Synaptic vesicles were labeled just above the background
level determined for mitochondria, suggesting an exclusion of
PrP C from this structure.
Proteins linked to the plasma membrane by either a GPI an-
chor or a transmembrane domain travel along the secretory path-
way. This begins with the synthesis of the protein, then translo-
cation into the ER, and finally movement through the Golgi
complex toward the final destination, the plasma membrane. At
various stages along the pathway, the proteins may become con-
centrated. We therefore analyzed the distribution of PrP C on
various organelles and membranes that are involved with the
trafficking pathway from four hippocampal cell populations: py-
ramidal neurons (CA1), granule neurons (dentate gyrus), hilar
neurons, and CPrP cells. We quantified the distribution in the
same manner as for the neuropil, counting the number of gold
particles per micrometer of organelle membrane (Table 2). The
data are grouped according to cell type (pyramidal neurons, gran-
ule neurons, hilar neurons, and CPrP cells)
and organelles (ER, Golgi, endosomes,
transport vesicles, and plasma membrane).
The overall distribution of gold particles was
similar in all types of cells analyzed. The low-
est concentration of PrPC was detected in the
ER and Golgi complex. An increase in PrPC
concentration occurs on the plasma mem-
brane and in late endosomes–multivesicular
bodies. Our findings correlate nicely with
previously published results about the folate
receptor, a GPI-anchored protein in cul-
tured cells (Mayor et al., 1998; Chatterjee et
al., 2001). Labeling for cytPrP was negligible
in all neurons except CPrP cells, in which the
number of gold particles exceeded 200
times the usual background level from the
three other types of neurons (Table 3).
The statistical significance of labeling
for cytPrP was assessed by the RLI (May-
hew et al., 2002) on the basis of a compar-
ison between the expected and observed
distributions of the gold particles. The ex-
pected gold particle distribution is derived
from a lattice of test points used for mor-
phometric counting. The null hypothesis
corresponds to a random distribution
(RLI 1) of the marker between compart-
ments such as the nucleus, mitochondria,
and cytosol. The RLI for PrP in the cytosol
of CPrP cells attained a value of 3.12 (Ta-
ble 4), which indicates preferential non-
random labeling. The total 2 value (the
sum of partial values) is 1864.2, indicating
that the null hypothesis must be rejected
( p  0.001). The partial 2 values show
that the most important contributor to the
total 2 value is cytPrP.
Discussion
We determined the ultrastructural distri-
bution of PrP C in murine hippocampus
using a number of recombinant Fabs gen-
erated against different parts of PrP C, the N terminus, central
region, and C terminus. In addition, we also present the first
quantitative data on the localization of PrP C in the CA1 region
and dentate gyrus of the hippocampus of several lines of wt in-
bred mice.
We found the following: (1) PrP C generally follows the stan-
dard biosynthetic trafficking pathway in brain neurons with
prominent presence in endosomes and the plasma membrane;
(2) PrP C has a ubiquitous distribution on the neuronal plasma
membrane and cellular processes without preferential accumula-
tion at synaptic specializations; (3) PrP C is found with the same
frequency on presynaptic as well as postsynaptic membranes and
within the synapse; (4) PrP C is almost excluded from the mem-
brane of synaptic vesicles; and (5) PrP is expressed in the cytosol
in a small population of neurons in the hippocampus, thalamus,
and somatosensory neocortex but not in the cerebellum.
Localization and quantification of PrP C in the hippocampus
At the light microscopic level, we saw preferential PrP C labeling
of the strata oriens, radiatum, and moleculare of the dentate gy-
Figure 6. PrP is concentrated in the cytosol (black arrowheads) in a population of neurons. A, Gold particles also label PrP in the
ER lumen (black arrows), Golgi cisternae and vesicles (white arrowheads), and in late endosomes (B, white arrowheads). C,
Although cells that are positive for cytPrP have a denser cytosol than surrounding neurons, this is not a distinctive feature because
there are cells with a dense cytosol displaying only membrane-bound PrP C labeling on the plasma membrane (black arrows) and
intracellular organelles (white arrowheads). D, Direct immunolabeling with Fab D18 demonstrates the same cytPrP abundance as
seen with indirect labeling methods (compare with A and B). The space indicated by the opposing arrows shows the lumen of the
ER. er, Endoplasmic reticulum; G, Golgi complex; le, late endosome; m, mitochondria; n, nucleus; pm, plasma membrane. Scale
bars, 200 nm.
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rus, which closely resembles previous re-
sults (Sales et al., 1998; Moya et al., 2000).
Because of an abundance of synapses in
these areas, it was concluded that the pat-
tern of staining is “very close to synaptic in
nature” and similar to the rab3 labeling
(Moya et al., 2000). The punctate appear-
ance of labeling could reflect the local con-
centrations of GPI-anchored proteins on
the plasma membrane of neurites, as
shown previously (Madore et al., 1999).
Furthermore, double labeling for PrP C
and either synaptophysin (Fournier et al.,
2000) or rab3 (Moya et al., 2000) was not
resolved well enough to claim unambigu-
ously the colocalization of these proteins
on the same subcellular structure. We
demonstrated clearly that synaptobrevin
and PrP C are localized on separate synap-
tic compartments. Therefore, we argue
against a significant biological role of PrP C
in synaptic vesicles. However, it does not
preclude an indirect role.
The very low level of labeling of synap-
tic vesicles in our study does not deny the
potential involvement of the synapse in
the pathogenesis of prion diseases, as pro-
posed by Fournier et al. (2000). The exclu-
sion of PrP C from synaptic vesicles in our
studies correlates with the morphological
and biochemical data by Laine et al. (2001)
and Herms et al. (1999). The presence of PrP C in all parts of the
plasma membrane, whether somatic, axonal, synaptic, or dendritic
membranes (with the highest concentration on the last), argues for
a more general physiological function than merely a synaptic one.
Various potential functions have been proposed by several authors,
including oxidative stress protection (Brown et al., 2001), copper
metabolism (Pauly and Harris, 1998), signal transduction
(Mouillet-Richard et al., 2000), and mediator of intercellular con-
tacts (Rieger et al., 1999; Schmitt-Ulms et al., 2001).
The relative concentration of PrP C in organelles along the traf-
ficking pathway observed in our study agrees well with the general
theory that proteins are concentrated along this pathway en route to
the plasma membrane. Here, we present quantitative morpholog-
ical results on the localization and concentration of PrP C in sub-
cellular organelles of the trafficking pathway in neurons in situ.
These results are in agreement with the intracellular retention of
GPI-anchored proteins in endosomal compartments (Mayor et al.,
1998) and with data concerning the recycling of PrP C from plasma
membranes via endosomes (Shyng et al., 1993). Reports on the
concentration of PrP Sc in endosomal and lysosomal structures
(Caughey et al., 1991; McKinley et al., 1991; Borchelt et al., 1992;
Taraboulos et al., 1992b; Arnold et al., 1995) underscore the im-
portance of these sites for PrP C degradation and possibly PrP C-to-
PrP Sc conversion.
The absence of PrP labeling in clathrin-coated structures con-
tradicts the suggestions by Laine et al. (2001). However, their data
could be attributed to either the possible diffusion of the peroxidase
reaction product to nearby locations, giving false-positive results,
or too low concentrations of PrP C in clathrin-coated structures,
which were undetectable by our immunogold procedure. Because
Figure 7. Cells with cytPrP are probably of a neuronal nature and have a functional GPI-
biosynthetic machinery. A, Cells with cytPrP receive synaptic input from other neurons on their
cell body and dendrites. B, An axonal terminal shows high labeling for PrP C and is most likely
derived from a CPrP cell. Because of the high abundance of synaptic vesicles, the exact localiza-
tion of PrP C is unclear. C, Normal CA1 pyramidal neurons have no PrP (small particles) or Thy-1
(big particles; arrows) in cytosol. PrP C and Thy-1 are concentrated in the Golgi complex and late
endosomes. D, CPrP cells demonstrate both cytosolic and membrane-bound PrP (small parti-
cles) and only membrane-bound Thy-1, another GPI-anchored protein (big particles; arrows).
at, Axon terminal; den, dendrite; er, endoplasmic reticulum; G, Golgi complex; m, mitochondria;
le, late endosome; sb, synaptic bouton. Scale bars, 200 nm.
Figure 8. Correlated light (A–C) and electron ( D, E) microscopic pictures of the same CPrP cell. A–C, Serial semithin hippocam-
pal sections labeled against PrP C (red) and TUNEL staining (green). A, Section treated with 1 U per 1 ml of DNaseI as the positive
control. Nuclei from all cells are highly fluorescent, indicating broken DNA strands. B, C, Serial sections not treated with DNaseI.
CPrP and pyramidal neurons show no signal for broken DNA strands, indicating that these cells are not apoptotic. The asterisk in C
indicates a cell imaged by EM in D. D, Low-magnification EM image of the cell marked with an asterisk in C. The blue line delineates
the border of the CPrP cell. Note the absence of chromatine clumping. E, Higher magnification of the rectanglular area in D with
cytosolic immunogold (15 nm) labeling against PrP. The majority of the immunogold is localized in the cytosol (arrowheads). er,
Endoplasmic reticulum; m, mitochondria; n, nucleus; pm, plasma membrane. Scale bars: (in C) A--C, 50m; D, 2m; E, 200 nm.
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it is known that neurons do not have calveoli, we can speculate
that PrP C recycles through endosomes via a nonclathrin, noncal-
veoli pathway (Peters et al., 2003).
The almost ubiquitous distribution of PrP C on the neuronal
plasma membrane and cellular processes without a preferential
accumulation at synaptic specializations suggests the absence of
active retention mechanisms, allowing unhampered diffusion of
PrP C along cellular membranes. This diffusion could play a ma-
jor role in PrP Sc propagation, because it was shown that a defec-
tive fast axonal transport did not interfere with prion neuroinva-
sion (Kunzi et al., 2002). It is entirely plausible that PrP Sc, which
retains the GPI anchor, could physically contact PrP C on adja-
cent cells or even be physically translocated to the membranes
from neighboring cells (Liu et al., 2002) at sites of very close
apposition to cellular membranes, including at the synapse. Ad-
ditionally, the finding of significant PrP C labeling in myelin
sheaths points to the possible involvement of oligodendrocytes in
the propagation of prion diseases.
Neurons containing cytPrP
Our studies revealed the existence of neurons containing cytPrP.
These cells showed a very different morphology from glial cells and
are negative for GFAP (an astroglial marker) and CNPase and S100
(oligodendrocytic markers). We observed synapses on cell bodies
and processes as well as axonal terminals with a high PrPC content,
which probably belong to CPrP cells. On the basis of our LM and EM
observations, we assumed CPrP cells to be of
neuronal nature. However, we are still focus-
ing our efforts on identifying the neuronal
subtype. An antibody against GABA (the
most commonly used marker for interneu-
rons) did not give any positive labeling in
cryosections. We believe that this can be ex-
plained by the fact that a very small molecule,
such as GABA, is not adequately retained in
cryosections, despite the use of glutaralde-
hyde. The additional cross-linking through
an embedding medium, such as resin, may
be necessary to preserve GABA localization
in ultrathin sections (Bouzamondo et al.,
2000), but it inevitably destroys the antigen
sites for PrPC antibodies (our unpublished
observations).
PrP accumulation in the cytosol might
depend on the circadian cycle of the cells or
reflect damage and stress. However, mor-
phological examination of these neurons did not show any or-
ganelle swelling, disaggregating of polyribosomes, or breaks in
the cell and nuclear membranes that are indicative of neuronal
necrosis. Furthermore, we did not find any morphological or
immunocytochemical apoptotic indicators. The absence of
TUNEL labeling revealed that CPrP cells do not possess breaks in
nuclear DNA that are characteristic of apoptotic cells. Therefore,
we conclude that these cells did not suffer any observable damage
that could be responsible for the unusual localization of PrP.
Although it seems unusual for a cell to have a protein in two
such distinct locations (the membranes of the trafficking path-
way and the cytosol), it is entirely plausible that a protein such as
PrP C could have roles in more than one compartment of a cell
(Hegde and Lingappa, 1999). Such a diversity of function from a
single gene has been observed for the protein calreticulin, which
was found to function in the ER, cytosol, and nucleus (Smith and
Koch, 1989; Burns et al., 1994; Coppolino et al., 1997). Similarly,
dual localization of other proteins or protein domains has also
been described for the plasminogen activator protein (Belin et al.,
1996) and the hepatitis B virus envelope protein (Swameye and
Schaller, 1997). It has been shown that PrP C has a rather complex
signal sequence, which directs it to the lumen of the ER (Zhang
and Ling, 1995; Hegde et al., 1998; Holscher et al., 2001; Kim et
al., 2001). Therefore, it is possible that the synthesis of the differ-
ent topological forms of PrP C varies between different cell types,
Table 2. Quantification of PrPC labeling on the membrane in different neuronal populations in the CA1 area and
dentate gyrusa
Neurons
Endoplasmic
reticulum Golgi complex
Endosomes/
lysosomes
Plasma
membrane Mitochondria
Pyramidal (n 18) 0.44 0.03 0.71 0.03 1.4 0.2 1.37 0.11 0.037 0.002
Hilar (n 18) 0.23 0.01 0.4 0.01 0.59 0.06 0.58 0.04 0.03 0.01
Granule (n 21) 0.25 0.01 0.36 0.03 0.58 0.07 0.64 0.03 0.03 0.01
CPrP cells (n 20) 0.38 0.02 0.64 0.05 1.51 0.12 1.53 0.08 0.06 0.008
aValues are number of gold particles per 1 m of membrane (gold per micrometer) in 77 cells from three different animals, given as mean  SEM.
Mitochondrial membranes were used to assess background labeling.
Table 3. Quantification of gold-labeled PrP in the cytosol in different populations of neuronsa
Neurons Nucleus Mitochondria Cytosol
Pyramidal (n 18) 0.12 0.04 0.87 0.6 0.09 0.04
Hilar (n 18) 0.14 0.08 1.09 0.73 0.09 0.04
Granule (n 21) 0.11 0.04 0.54 0.26 0
CPrP cells (n 20) 0.845 0.16 2.6 0.53 23.4 3.6
aGold particles were quantified over an area of the cytosol that was free of organelles. To assess background labeling, gold particles were quantified over the
area of mitochondria and nucleus (gold per square micrometer). Results are presented as mean SEM.
Table 4. Observed and expected distributions of gold particles in compartments of pyramidal neurons and CPrP cells, relative labeling index, and2 valuesa
Compartments
Number of observed
gold particles, no
Number of
grid points, P
Normalized number of
expected gold particles,
ne P(total no/total P)
Relative labeling
index, no/ne
Partial2 values,
(no ne)
2/ne
Pyramidal neurons
Nucleus 11 421 181 0.06 160
Mitochondria 5 69 30 0.24 20
Cytosol 13 799 344 0.04 318
CPrP cells
Nucleus 26 227 98 0.27 51
Mitochondria 27 105 45 0.6 7.2
Cytosol 908 678 292 3.12b 1308b
Totals 990 2299 990 1 1864.2c
aThe values were quantified for 10 cells in each category.
bIndicates compartment is preferentially labeled.
cThe distribution is nonrandom, with p 0.001.
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according to the expression of different cytoplasmic components
of the translocation machinery (Hegde and Lingappa, 1999).
The dislocation of PrP from the ER to the cytosol has been
demonstrated previously in cell culture systems under certain
conditions, such as in a reducing environment and glycosylation
(Ma and Lindquist, 2001) or proteosomal (Yedidia et al., 2001)
inhibition. This could explain the presence of cytPrP in situ.
However, the absence of GPI-anchored Thy-1 in the cytosol of
CPrP cells argues that other GPI-anchored proteins preserve
their usual localization. Because proteosome inhibition should
affect many proteins, an unknown specific mechanism for PrP
accumulation in the cytosol may be present.
It was recently shown that transfected cytPrP appears to be
toxic in both cell culture and transgenic animals, in a cell type-
dependent manner. Only cerebellar cells appeared to be affected
in mice that expressed PrP C without an ER translocation signal
(Ma et al., 2002). Accumulation of cytPrP in “susceptible” neu-
rons might be responsible for some of the variants of prion dis-
eases in which cytPrP aggregates kill the cell and cause release of
infectious prions. These prions might then initiate the vicious
circle of prion propagation. However, our studies show that
cytPrP is present in normal rodent brains in a population of
neurons that appears healthy and shows no cellular degeneration.
Thus, we can infer that cytPrP is not toxic in some neurons but
highly toxic when overexpressed in specific cell populations.
More work is needed to elucidate the causes of such striking
differences resulting from cytPrP.
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